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BACKGROUND
Thyroid peroxidase antibodies are associated with an increased risk of miscarriage 
and preterm birth, even when thyroid function is normal. Small trials indicate that 
the use of levothyroxine could reduce the incidence of such adverse outcomes.
METHODS
We conducted a double-blind, placebo-controlled trial to investigate whether levo-
thyroxine treatment would increase live-birth rates among euthyroid women who 
had thyroid peroxidase antibodies and a history of miscarriage or infertility. A total 
of 19,585 women from 49 hospitals in the United Kingdom underwent testing for 
thyroid peroxidase antibodies and thyroid function. We randomly assigned 952 
women to receive either 50 μg once daily of levothyroxine (476 women) or placebo 
(476 women) before conception through the end of pregnancy. The primary out-
come was live birth after at least 34 weeks of gestation.
RESULTS
The follow-up rate for the primary outcome was 98.7% (940 of 952 women). A total 
of 266 of 470 women in the levothyroxine group (56.6%) and 274 of 470 women in 
the placebo group (58.3%) became pregnant. The live-birth rate was 37.4% (176 of 
470 women) in the levothyroxine group and 37.9% (178 of 470 women) in the placebo 
group (relative risk, 0.97; 95% confidence interval [CI], 0.83 to 1.14, P = 0.74; absolute 
difference, −0.4 percentage points; 95% CI, −6.6 to 5.8). There were no significant 
between-group differences in other pregnancy outcomes, including pregnancy loss 
or preterm birth, or in neonatal outcomes. Serious adverse events occurred in 5.9% 
of women in the levothyroxine group and 3.8% in the placebo group (P = 0.14).
CONCLUSIONS
The use of levothyroxine in euthyroid women with thyroid peroxidase antibodies did 
not result in a higher rate of live births than placebo. (Funded by the United Kingdom 
National Institute for Health Research; TABLET Current Controlled Trials num-
ber, ISRCTN15948785.)
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Miscarriage, which occurs in one of five women who conceive, is one of the most common complications of 
pregnancy.1 Preterm birth, which occurs in ap-
proximately 7% of live births, is the single larg-
est cause of neonatal complications and death.2 
Both miscarriage and preterm birth substan-
tially affect the physical and psychological well-
being of prospective parents and have major cost 
implications for patients and health institutions.
A systematic review of 31 studies involving 
euthyroid women showed a strong association 
between the presence of thyroid peroxidase an-
tibodies and miscarriage (odds ratio, 3.90; 95% 
confidence interval [CI], 2.48 to 6.12; P<0.001) 
and preterm birth (odds ratio, 2.07; 95% CI, 
1.17 to 3.68; P = 0.01). Studies included in the 
systematic review involved women with recurrent 
miscarriage, infertile women, and unselected pop-
ulations.3
Three randomized trials have examined the 
use of levothyroxine in women with thyroid per-
oxidase antibodies and normal thyroid function. 
The pooled results of the first two trials, one 
involving an unselected population of 115 wom-
en4 and the other involving 72 women undergo-
ing assisted conception,5 showed a substantially 
lower incidence of miscarriage among women 
taking levothyroxine than among those who re-
ceived placebo or no treatment (relative risk, 0.48; 
95% CI, 0.25 to 0.92; P = 0.03).3 A third trial, the 
results of which were published after our trial 
began, was limited to women undergoing in vitro 
fertilization. It showed that the use of levothyrox-
ine did not reduce the incidence of miscarriage or 
preterm birth.6 That trial involved 600 women, 
among whom there was a total of 220 pregnan-
cies and 23 miscarriages. Evidence to support 
the use of levothyroxine has therefore remained 
inconclusive.
The 2017 guidelines of the American Thyroid 
Association stated that “insufficient evidence ex-
ists to conclusively determine whether LT4 [levo-
thyroxine] therapy decreases pregnancy loss risk 
in TPOAb-positive [thyroid peroxidase antibody–
positive] euthyroid women who are newly preg-
nant” and recommended that “administration of 
LT4 to TPOAb-positive euthyroid pregnant wom-
en with a . . . history of loss may be considered 
given its potential benefits in comparison with 
its minimal risk.”7 The guideline task force drew 
attention to our ongoing trial.7 We designed the 
multicenter, randomized, placebo-controlled Thy-
roid Antibodies and Levothyroxine (TABLET) trial 
to investigate whether the use of levothyroxine 
would increase the rates of live births after at least 
34 weeks of gestation among euthyroid women 
with thyroid peroxidase antibodies.
Me thods
Trial Oversight
Our trial was approved by the United Kingdom 
Medicines and Healthcare Products Regulatory 
Authority, the National Research Ethics Service, 
and the research department at each participating 
hospital. Generic levothyroxine and placebo were 
packaged and supplied by Sharp HealthCare (for-
merly Bilcare United Kingdom), which had no role 
in the design of the trial; the collection, analysis, 
or interpretation of the data; or the writing of 
the manuscript. Trial oversight and monitoring 
were provided by a trial steering committee and 
by an independent data and safety monitoring 
committee. The first, second, and last authors 
vouch for the accuracy and completeness of the 
data and analyses and for the fidelity of the trial 
to the protocol (available with the full text of 
this article at NEJM.org).
Trial Participants
The participants were recruited from 49 hospitals 
across the United Kingdom. We originally re-
stricted the trial population to women who had 
had one or more miscarriages. However, owing 
to the lower-than-expected prevalence of thyroid 
peroxidase antibodies, which became evident 
within the first 6 months after the beginning of 
trial recruitment, we expanded the recruitment 
to include women who were receiving treatment 
for infertility, since data from cohort studies had 
shown an association between miscarriage and 
thyroid autoantibodies in the population with 
infertility.3 This also allowed our results to be 
generalizable to both populations. Women were 
eligible for enrollment in the trial if they were 16 
to 40 years of age, had a history of miscarriage or 
infertility, and were trying to conceive in the sub-
sequent 12 months (either naturally or through 
assisted conception). Women were excluded if they 
were receiving treatment for a thyroid disorder, 
had cardiac disease, or were receiving amioda-
rone or lithium.
The screening stage involved tests to detect 
thyroid peroxidase antibodies and thyroid-func-
tion tests. Euthyroidism was defined as a thyro-
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tropin level of 0.44 to 3.63 mIU per liter and a 
free thyroxine (T4) level of 10.0 to 21.0 pmol per 
liter as measured with one of these specified 
analyzers: Abbott ARCHITECT (Fisher Scientific); 
Elecsys, Modular, or Cobas (Roche); and ADVIA 
Centaur (Siemens [Bayer]). The euthyroid refer-
ence range covered the second and third quartiles 
of all accepted assays. Thyroid peroxidase anti-
body positivity was defined according to indi-
vidual hospital laboratory thresholds, which are 
known to produce results with greater than 99% 
concordance in the U.K. Immunology, Immuno-
chemistry, and Allergy National External Quality 
Assurance Service (NEQAS IIA) analysis.8 A list 
of the analyzers and corresponding thresholds is 
provided in Table S1 in the Supplementary Ap-
pendix, available at NEJM.org. Women who were 
found to have normal thyroid function and thy-
roid peroxidase antibody positivity were then 
invited to take part in the trial. All participants 
provided written informed consent for both the 
screening tests and trial participation.
Trial Design and Drug Regimen
Participants were randomly assigned in a 1:1 ratio 
to receive oral capsules containing either 50 μg 
of levothyroxine or matched placebo once a day. 
Administration of the trial agents began imme-
diately after randomization. The appearance, route, 
and timing of the administration of the trial agents 
were identical in the two groups. Throughout the 
duration of the trial, the participants, clinicians, 
and trial nurses were unaware of the trial-group 
assignments.
Computerized randomization was performed 
centrally through a secure Internet application. 
Minimization was used to balance the trial-group 
assignments according to age (<35 or ≥35 years), 
the number of previous miscarriages (0, 1, 2, or 
≥3), infertility treatment (yes or no), and the base-
line thyrotropin concentration (≤2.5 or >2.5 mIU 
per liter).
The use of the trial agent was initiated before 
conception and continued until the end of preg-
nancy. After randomization, women underwent a 
12-month evaluation. Participants were instructed 
to contact their local trial team as soon as they 
had a positive urinary pregnancy test. During 
the 12-month period when the women were trying 
to conceive, they returned to the hospital every 
3 months to undergo thyroid-function testing, 
report adverse events, and obtain a new supply of 
the trial agent. Once pregnant, the women had 
three trial visits, including thyroid-function test-
ing, at 6 to 8 weeks, 16 to 18 weeks, and 28 weeks. 
Test results outside of assay-specific limits were 
managed locally by the relevant clinicians, and 
the trial agent was discontinued. Outcomes in all 
women who underwent randomization (pregnant 
and nonpregnant) were included in the trial in-
tention-to-treat analysis.
Adherence to the trial agent was primarily as-
certained by pill counting at the scheduled trial 
visits; trial participants were also asked questions 
about adherence. The pharmacokinetic properties 
of levothyroxine suggest that missing tablets inter-
mittently is unlikely to substantively affect thyrox-
ine bioavailability.9 Therefore, good adherence was 
defined a priori by pill counts or verbal confir-
mation (in cases in which pill counts were not 
available) indicating that at least 75% of the pills 
were taken.
Outcome Measures
The primary outcome was the percentage of 
women who underwent randomization and had a 
live birth after at least 34 completed weeks of ges-
tation. Prespecified secondary outcomes included 
the following: clinical pregnancy at 7 weeks; 
ongoing pregnancy at 12 weeks; miscarriage 
before 24 weeks; stillbirth (intrauterine death at 
≥24 weeks); ectopic pregnancy; termination of 
pregnancy; live birth before 28 weeks, before 34 
weeks, and before 37 weeks; the week of gesta-
tion at delivery; birth weight (in grams); and Apgar 
scores at 1 and 5 minutes. Maternal antenatal, 
intrapartum, and postnatal complications and 
neonatal complications were also included in the 
prespecified secondary outcomes. Table S2 in the 
Supplementary Appendix provides a complete list 
of prespecified trial outcomes.
Gestational age was determined with the use 
of crown–rump length from ultrasonographic 
measurement in the first trimester when available. 
Otherwise, it was based on the date of the last 
menstrual period.
Statistical Analysis
We calculated that we would need to assign 760 
women (380 in each group) for the trial to have 
80% power to detect a minimally important dif-
ference of 10 percentage points between the levo-
thyroxine group and the placebo group with re-
spect to the rate of live births (65% vs. 55%) 
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after at least 34 weeks of gestation at a two-
sided P  value of  0.05. The minimally important 
difference was estimated on the basis of consul-
tations among health care practitioners, patients, 
and representatives of patient organizations. The 
baseline live-birth rate of 55% in the control group 
was based on the assumption that 10% of un-
selected women would not conceive within 1 year10 
and a further 35% would either miscarry or have 
a preterm birth.1 We planned to include 900 par-
ticipants in the trial to account for a 15% loss to 
follow-up.
Analyses were conducted as prespecified in 
our statistical analysis plan. Estimates of differ-
ences between the groups for the primary out-
come are presented with 95% confidence inter-
vals and P values from two-sided tests at the 5% 
significance level. The statistical analysis plan did 
not include a provision for correction for multiple 
comparisons when tests were conducted for sec-
ondary or other outcomes. Therefore, the results 
for these outcomes are reported as point esti-
mates and 95% confidence intervals. The widths 
of the confidence intervals were not adjusted for 
multiple comparisons, so the intervals should 
not be used to infer definitive treatment effects.
For the primary outcome (live birth at ≥34 
weeks of gestation), the trial population consisted 
of all participants who underwent randomization 
(intention-to-treat population). For maternal preg-
nancy outcomes (e.g., miscarriage and stillbirth), 
the analysis population consisted of all women 
who had a confirmed pregnancy. Confirmation 
of pregnancy was initially by a positive urinary 
pregnancy test, followed by an ultrasonographic 
examination at 6 to 8 weeks. Women who had 
an empty uterus at the follow-up ultrasonograph-
ic examination or who reported a negative preg-
nancy test subsequent to a positive test were clas-
sified as having had a miscarriage. Log-binomial 
regression was used to generate relative risks, with 
adjustment for the minimization variable for all 
binary outcomes. A Cox proportional-hazards 
model was used for the time from conception to 
the end of pregnancy and the time from concep-
tion to birth. A linear regression model was 
used for continuous outcomes.
Sensitivity analyses were performed for the 
primary outcome and the outcome of miscarriage 
at less than 24 weeks, under the assumption that 
all patients who withdrew from the trial or were 
lost to follow-up did not have a live birth at or 
after 34 weeks. Prespecified subgroup analyses 
were completed for the primary outcome accord-
ing to maternal age (<35 or ≥35 years), the num-
ber of previous miscarriages (0, 1 or 2, or ≥3), 
the initial thyrotropin concentration (≤2.5 mIU 
per liter or >2.5 mIU per liter), and infertility 
treatment (yes or no). Further exploratory sub-
group analyses were also prespecified: race or 
ethnic group (black, white, Chinese, South Asian, 
or other), baseline level of thyroid peroxidase anti-
bodies (≥50th percentile [very high] or <50th per-
centile [high]), and body-mass index (the weight in 
kilograms divided by the square of the height in 
meters; <25 or ≥25). The effects of these sub-
groups were examined by adding the subgroup 
according to trial-group interaction variables to 
the log-binomial model.
Interim analyses of effectiveness and safety 
end points were performed on behalf of the data 
and safety monitoring committee at approximately 
6-month intervals during the recruitment period. 
Because these analyses were performed with the 
use of the Haybittle–Peto principle,11 no adjust-
ment was made in the final P values to determine 
significance. All analyses were performed with the 
use of SAS software, version 9.4 (SAS Institute).
R esult s
Trial Participants
A total of 19,556 women underwent tests to detect 
thyroid peroxidase antibodies and thyroid-function 
tests between December 2011 and January 2016. Of 
these women, 1420 were eligible for enrollment in 
the trial, of whom 952 consented to participate and 
were randomly assigned to receive either levothy-
roxine (476 women) or placebo (476 women). The 
follow-up rate for the primary outcome was 98.7% 
(940 of 952 women); 6 women from each group 
were lost to follow-up or withdrew consent. A total 
of 266 of 470 women in the levothyroxine group 
(56.6%) and 274 of 470 women in the placebo 
group (58.3%) became pregnant (Fig. 1). The base-
line characteristics were similar in the two groups 
(Table 1, and Table S3 in the Supplementary Ap-
pendix).
Outcomes
Among all women who underwent randomiza-
tion, the live-birth rate after at least 34 weeks of 
gestation was 37.4% (176 of 470 women) in the 
levothyroxine group, as compared with 37.9% 
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(178 of 470 women) in the placebo group (relative 
risk, 0.97; 95% CI, 0.83 to 1.14; P = 0.74; absolute 
risk difference, 0.4 percentage points; 95% CI, 
−6.6 to 5.8) (Table 2). There was no significant 
between-group difference in the results in sensi-
tivity analyses (Table S4 in the Supplementary 
Appendix) nor in any of the preplanned subgroup 
analyses (Fig. 2).
There were no significant between-group differ-
ences with respect to any of the secondary out-
comes (Table 2, and Table S5 in the Supplementary 
Appendix). The distributions of gestational age at 
the time of live-birth delivery were similar in the 
two trial groups (Fig. S1 in the Supplementary 
Appendix). No significant differences were noted 
in the incidence of maternal or neonatal complica-
tions (Table S6 in the Supplementary Appendix).
As expected, at every time point, the serum 
thyrotropin concentrations were lower and the free 
T4 concentrations were higher in the levothyroxine 
group than in the placebo group (Table S7 and 
Figs. S2 and S3 in the Supplementary Appendix); 
this indicates a biologic effect of levothyroxine. 
The percentages of women who discontinued the 
trial agent because of abnormal results on thyroid-
function tests were similar in the levothyroxine 
and placebo groups (9.8% and 9.6%, respectively) 
(Table S8 in the Supplementary Appendix). In 
women for whom adherence data were reported, 
adherence was good, ranging from 81% to 94% 
Figure 1. Enrollment, Randomization, Follow-up, and Analysis.
952 Underwent randomization
19,556 Women were assessed for eligibility
18,136 Were not eligible
16,162 Did not have thyroid peroxidase
antibodies
1,492 Had thyroid-function levels out
of reference range
482 Had other or unknown reason
1420 Were assessed for eligibility
468 Did not undergo randomization
476 Were assigned to receive levothyroxine 476 Were assigned to receive placebo
6 Were excluded
4 Withdrew consent
2 Were lost to follow-up
6 Were excluded
1 Withdrew consent
5 Were lost to follow-up
470 Were included in the primary
outcome analysis
 470 Were included in the primary
outcome analysis
266 Were pregnant 204 Were not pregnant 274 Were pregnant 196 Were not pregnant
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across all time points (Table S8 in the Supplemen-
tary Appendix).
Serious adverse events occurred in 28 women 
in the levothyroxine group (5.9%) and in 18 in the 
placebo group (3.8%) (P = 0.14) (Table S9 in the 
Supplementary Appendix). The reported symptoms 
at each follow-up visit are listed in Table S10 in 
the Supplementary Appendix.
Characteristic
Levothyroxine Group 
 (N = 476)
Placebo Group 
(N = 476)
General demographic characteristics
Maternal age†
<35 yr — no. (%) 306 (64.3) 306 (64.3)
Mean age — yr 32.5±4.9 32.7±4.9
BMI
BMI ≥25 — no./total no. (%) 240/462 (51.9) 240/464 (51.7)
Mean BMI 26.4±5.6 26.5±5.5
Race or ethnic group — no. (%)‡
White 328 (68.9) 337 (70.8)
Chinese 4 (0.8) 4 (0.8)
South Asian 110 (23.1) 94 (19.7)
Black 16 (3.4) 23 (4.8)
Other 18 (3.8) 18 (3.8)
Pregnancy history
Nulliparous — no./total no. (%) 141/476 (29.6) 131/473 (27.7)
Previous miscarriages — no./total no. (%)†
0 166/476 (34.9) 165/476 (34.7)
1 or 2 219/476 (46.0) 213/473 (45.0)
≥3 91/476 (19.1) 95/476 (20.0)
No. of previous miscarriages — median (IQR)
In women with ≥1 miscarriage 2 (1–3) 2 (1–3)
First‑trimester miscarriage (<14 wk) in women with ≥1 miscarriage 2 (1–3) 2 (1–3)
Previous preterm births at <34 wk — no./total no. (%) 11/476 (2.3) 10/473 (2.1)
Current treatment for infertility — no. (%)† 216 (45.4) 213 (44.7)
Prerandomization thyroid hormone concentrations
Serum thyrotropin level†
≤2.5 mIU/liter — no. (%) 329 (69.1) 330 (69.3)
>2.5 mIU/liter — no. (%) 147 (30.9) 146 (30.7)
Median level (IQR) — mIU/liter 2.10 (1.51–2.74) 2.01 (1.45–2.70)
Level on log scale — mIU/liter 0.674±0.422 0.652±0.418
Mean serum free thyroxine level — pmol/liter 14.6±1.9 14.5±2.0
Median serum thyroid peroxidase antibody level (IQR) — IU/ml§ 170 (83–428) 202 (94–417)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. There were no significant differences between the 
groups in the listed characteristics at baseline. To convert the values for free thyroxine to nanograms per deciliter, divide by 12.87. BMI de‑
notes body‑mass index, and IQR interquartile range.
†  This variable was a minimization variable.
‡  Race or ethnic group was reported by the participants.
§  Data were missing for six women in the levothyroxine group and four women in the placebo group.
Table 1. Baseline Characteristics of the Participants.*
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Outcome
Levothyroxine 
 Group
Placebo 
 Group
Relative Risk 
 or Mean Difference 
 (95% CI)†
Primary outcome
Live birth at ≥34 wk — no./total no. (%) 176/470 (37.4) 178/470 (37.9) 0.97 (0.83 to 1.14)
Secondary outcomes
Pregnancy at ≤12 mo after enrollment  
— no./total no. (%)
266/470 (56.6) 274/470 (58.3) 0.97 (0.88 to 1.07)
Pregnancy outcomes — no./total no. (%)
Clinical pregnancy at 7 wk‡ 237/266 (89.1) 248/274 (90.5) 0.98 (0.93 to 1.04)
Ongoing pregnancy at 12 wk‡ 194/266 (72.9) 200/274 (73.0) 1.00 (0.90 to 1.11)
Miscarriage at <24 wk§ 75/266 (28.2) 81/274 (29.6) 0.95 (0.73 to 1.23)
Stillbirth: intrauterine death at ≥24 wk 1/266 (0.4) 0/274 —
Ectopic pregnancy 3/266 (1.1) 6/274 (2.2) 0.50 (0.13 to 1.99)
Termination of pregnancy¶ 1/266 (0.4) 0/274 —
Live birth
At <34 wk 10/266 (3.8) 10/274 (3.6) 1.02 (0.43 to 2.42)
At ≥34 wk 176/266 (66.2) 178/274 (65.0) 1.02 (0.90 to 1.15)
Neonatal outcomes among women with live births  
at ≥24 wk
Gestational age at delivery
Wk of gestation 38 wk 6 days±2 wk 3 days 39 wk±2 wk 4 days 1 day (−0 wk 4 days to 0 wk 3 
days)
No. of women 186 188
Birth weight
Mean weight — g‖ 3226±660 3262±668 −35 (−168 to 97)
No. of infants 187 188
Apgar score
At 1 min
Median (IQR) 9 (9–9) 9 (8–9) 0.1 (−0.2 to 0.4)
No. of infants 179 178
At 5 min
Median (IQR) 9 (9–10) 9 (9–10) 0.0 (−0.2 to 0.2)
No. of infants 178 178
*  Plus–minus values are means ±SD. There were no significant differences between the groups.
†  Relative risks are shown for the primary outcome and all pregnancy outcomes listed as secondary outcomes. The mean difference is shown 
for all neonatal outcomes listed as secondary outcomes. For binary outcomes, a relative risk of less than 1 favors the levothyroxine group, 
except for live birth after at least 34 weeks of gestation, clinical pregnancy at 7 weeks, and ongoing pregnancy at 12 weeks, for which a rela‑
tive risk greater than 1 would favor levothyroxine. For continuous outcomes, mean differences greater than 1 favor the levothyroxine group. 
The widths of the confidence intervals have not been adjusted for multiple comparisons.
‡  Nine ectopic pregnancies were considered to be unviable and so were assumed to have ended on day 0. One pregnancy was terminated  
at 12 weeks, so it was counted as survival to this time. One missing date of miscarriage was assumed in this analysis to be between 7 and 
12 weeks (the period during which miscarriage typically occurs).
§  The median gestational age in the levothyroxine group was 8 weeks (IQR, 6 to 10), and the median gestational age in the placebo group 
was 9 weeks (IQR, 7 to 10). One woman in the placebo group who was pregnant with twins and who had both a live birth at less than  
34 weeks of gestation and a miscarriage was counted in both categories.
¶  The reason for termination of pregnancy was fetal abnormality (anencephaly).
‖  Eight birth weights were unknown in the levothyroxine group, and seven birth weights were unknown in the placebo group.
Table 2. Primary Outcome and Secondary Outcomes.*
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Discussion
In our multicenter, randomized, placebo-controlled 
trial, the use of levothyroxine, initiated before con-
ception and continued throughout pregnancy, did 
not result in a higher rate of live births after at 
least 34 weeks of gestation than placebo among 
thyroid peroxidase antibody–positive euthyroid 
women who had a history of miscarriage or in-
fertility. There was also no significant effect on 
other pregnancy or neonatal outcomes, includ-
ing the incidence of miscarriage and preterm 
birth.
Our trial was larger than previous studies, 
which were inadequately powered4,5 or restricted 
to a single population.5,6 Our inclusion of mul-
tiple centers and multiple clinical populations 
improved the generalizability of the findings.
One limitation of our trial is that we studied 
levothyroxine at a dose of 50 μg once daily. It is 
possible that the dose may need to be adjusted 
depending on the participant’s body weight, 
thyroid peroxidase antibody level, or thyrotropin 
concentration. The thyroid-function test thresh-
olds in our trial, which were used to assess the 
continuation of the trial agent at each time point, 
were within the limits that are considered to be 
safe during pregnancy. The frequency of with-
drawal from the trial agents was similar in the 
levothyroxine and placebo groups. Although wom-
en who received levothyroxine had significantly 
lower mean thyrotropin levels and higher free T4 
Figure 2. Prespecified Subgroup Analyses in Women Who Had a Live Birth after at Least 34 Weeks of Gestation.
The widths of the confidence intervals were not adjusted for multiple comparisons. The size of the black squares corresponds to the total 
number of women in the subgroup. Prespecified subgroup analyses included maternal age, the number of previous miscarriages, the 
thyrotropin concentration at baseline, and infertility treatment at the time of randomization. Prespecified “exploratory” subgroup analy‑
ses included the thyroid peroxidase antibody concentration at baseline, race and ethnic group, and the body‑mass index (BMI, the weight 
in kilograms divided by the square of the height in meters).
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0.96 (0.80–1.15)
1.02 (0.75–1.38)
0.83 (0.59–1.16)
1.02 (0.83–1.25)
1.04 (0.72–1.51)
1.00 (0.83–1.22)
0.91 (0.69–1.20)
1.03 (0.76–1.40)
0.95 (0.79–1.15)
1.08 (0.84–1.38)
0.85 (0.69–1.05)
0.91 (0.76–1.10)
1.11 (0.76–1.62)
1.25 (0.77–2.03)
1.01 (0.81–1.27)
0.97 (0.78–1.21)
0.97 (0.83–1.14)
0.50
P Value for
Interaction
123/302
  53/168
  44/157
  98/219
34/94
121/325
  55/145
  61/215
115/255
  79/217
  93/247
121/324
  37/108
18/38
  87/237
  87/219
176/470
124/301
  54/169
  51/151
  91/217
  36/102
120/327
  58/143
  58/209
120/261
  82/247
  95/219
132/334
30/92
16/44
  88/239
  88/221
178/470
0.74
0.55
0.59
0.67
0.16
0.40
0.78
0.74
no. of women/total no.
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concentrations than those who received placebo, 
this did not have a clinically relevant effect on 
the rates of thyroid dysfunction or clinical out-
comes.
Another potential limitation of our trial is the 
use of various assays for thyroid peroxidase an-
tibodies, each with different detection limits and 
thresholds for test positivity, that were predeter-
mined by the assay manufacturer. However, these 
variations are an accepted part of normal prac-
tice. Quality assurance for assays in the labora-
tories for all the participating centers is provided 
by U.K. NEQAS IIA (a national quality-assurance 
scheme), which shows greater than 99% concor-
dance in the classification of samples as either 
positive or negative for thyroid peroxidase anti-
bodies across all assays.8 With this assurance, the 
TABLET protocol did not define a single thresh-
old for thyroid peroxidase antibody positivity but 
accepted the classification of abnormality pro-
vided by the laboratories servicing the partici-
pating centers.
It was anticipated that broadening of the in-
clusion criteria to women with infertility might 
result in a decreased rate of live births and affect 
the power of the trial. However, the 95% confi-
dence interval for the primary outcome rules out 
a clinically meaningful benefit, and therefore a 
potential reduction in power does not affect our 
inferences.
In conclusion, our trial showed no signifi-
cant difference in rates of live births after at 
least 34 weeks of gestation with the use of 50 μg 
of levothyroxine once daily, started before con-
ception and continued throughout pregnancy, 
among euthyroid women with thyroid peroxi-
dase antibodies.
This report presents independent research commissioned by 
the National Institute for Health Research (NIHR). A mono-
graph reporting the data collected in this trial will be published 
in the NIHR Journals Library. Further information is available at 
www . journalslibrary . nihr . ac . uk/ programmes/ eme/ 0910010/ #/ . 
The views and opinions expressed in this article are those of the 
authors and do not necessarily reflect those of the NHS, the 
NIHR, the Medical Research Council, the Central Commission-
ing Facility, the NIHR Evaluation, Trials, and Studies Coordinat-
ing Centre, the efficacy and mechanism evaluation program, or 
the Department of Health.
Supported by the United Kingdom NIHR efficacy and mecha-
nism evaluation program (project number 09/100/10).
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
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